NCT04830397View on ClinicalTrials.gov

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

February 17, 2022

Study Completion Date

February 17, 2022

Conditions

Primary Open Angle GlaucomaOcular Hypertension

Interventions

DRUG

QLS-101

Ophthalmic solution 1x daily

DRUG

Timolol Maleate

Ophthalmic solution 1x daily

Trial Locations (1)

31701

Dixon Eye Care, Albany

All Listed Sponsors

lead

Qlaris Bio, Inc.

INDUSTRY

NCT04830397 - Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension). | Biotech Hunter | Biotech Hunter